Foghorn sounds another warning about the class of ‘20
In 2020 76 biotech floats raised a combined $12.7bn. Foghorn is not the first to show that much of the faith was misplaced.
Lilly’s oral interleukin exit hints at a dicey future
Liver toxicity with the group’s oral IL-17 inhibitor could raise doubts about projects from Dice, Leo and Sanofi.
Esmo 2021 – the jury remains out on CDK7 inhibition
Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
Biopharma acquisitions slow, but it's not Covid-19's fault yet
Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.
Amarin falls at obvious hurdle
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
Vascepa's future could hinge on next week's panel
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
